What role do atypical antipsychotic drugs have in treatment-resistant depression?

Journal of Clinical Psychiatry

Volumn 63, Issue 2, 2002, Pages 95-103

  Thase, Michael E ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BROMOCRIPTINE; BUSPIRONE; CHLORPROMAZINE; CLOZAPINE; DESIPRAMINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; HALOPERIDOL; LIOTHYRONINE; LIOTHYRONINE SODIUM; LITHIUM; MIRTAZAPINE; NEFAZODONE; NORADRENALIN; OLANZAPINE; PERPHENAZINE; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; THYROID HORMONE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DIARRHEA; DISEASE DURATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG POTENTIATION; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MOTOR DYSFUNCTION; NAUSEA; PARKINSONISM; PATIENT COMPLIANCE; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; SEDATION; SEROTONIN RELEASE; SEXUAL DYSFUNCTION; SLEEP DISORDER; SOMNOLENCE; TARDIVE DYSKINESIA; THERAPY RESISTANCE; WEIGHT GAIN;

EID: 0036177850     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n0202     Document Type: Article

References (84)

1. Long-term nature of depression
2. Antidepressants
3. Olanzapine and the new generation of antipsychotic agents: Patterns of use
4. Atypical antipsychotics for treatment of mixed depression and anxiety
5. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia
6. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression
7. Adjunctive use of olanzapine in mood disorders: Five case reports
8. Treatment-resistant depression: Methodological overview and operational criteria
9. Treatment-resistant depression
10. Treatment-resistant depression
11. Compliance and therapeutic issues in resistant depression
12. Paroxetine in the treatment of melancholia and severe depression
13. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: A double-blind, controlled study
14. Selecting the optimum therapeutic dose of serotonin reuptake inhibitors: Studies with citalopram
15. High-dose fluoxetine: Safety and efficiency in 27 cases
16. What to do with SSRI nonresponders?
17. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome
18. Chronological milestones to guide drug change: When should clinicians switch antidepressants?
19. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine
20. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investigation
21. New approaches to the treatment of refractory depression
22. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: A retrospective analysis
23. HMPAO SPECT brain imaging in treatment-resistant depression
24. Dopaminergic agents and stimulants as antidepressant augmentation strategies
25. Psychostimulant augmentation of second-generation antidepressants: A case series
26. Venlafaxine augmentation with methylphenidate for treatment-refractory depression: A case report
27. Pernoline augmentation for resistant depression
28. Modafinil augmentation of antidepressant treatment in depression
29. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression
30. Bromocripfine treatment of relapses seen during selective serotonin reuptake inhibitor treatment of depression
31. Survey and treatment strategy of antidepressant-resistant depression
32. Bromocriptine treatment of depressive disorders: Clinical and biochemical effects
33. Bromocriptine and imipramine in endogenous depression: A double-blind controlled trial in outpatients
34. A comparative, multicenter trial between bromocriptine and amitriptyline in the treatment of endogenous depression
35. Pramipexole augmentation in the treatment of unipolar and bipolar depression: A retrospective chart review
36. Major tranquilizers used as antidepressants: A review
37. Psychotic (delusional) major depression: Should it be included as a distinct syndrome in DSM-IV?
38. The use of antipsychotic drugs in the treatment of depression
39. Olanzapine in the treatment of psychotic depression
40. Risperidone monotherapy for psychotic depression unresponsive to other treatments
41. Olanzapine response in psychotic depression
42. Treatment of psychotic depression
43. Olanzapine in the treatment of depressive disorders with psychotic symptoms
44. Tranylcypromine plus risperidone for treatment-refractory major depression
45. Olanzapine plus fluoxetine: Double-blind and open-label results in treatment-resistant major depressive disorder
46. The mesolimbic dopamine system as a target for rapid antidepressant action
47. Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons
48. Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine
49. Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja
50. Induction patterns of fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity
51. Risperidone: Regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain
52. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex
53. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum
54. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, fisperidone, and sertindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials
55. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol
56. Blind, controlled, longterm study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
57. Hyperprolactinemia
58. Breast cancer in a male patient with prolactinoma
59. Implications of not treating hyperprolactinemia
60. Prolactin and antipsychotic medications: Mechanism of action
61. Risperidone side effects
62. Prolactin levels and adverse events in patients treated with risperidone
63. Risperidone-associated hyperprolactinemia
64. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
65. Olanzapine increases weight and serum triglyceride levels
66. Olanzapine-induced elevation of plasma triglyceride levels
67. Weight gain: Side effect of atypical neuroleptics?
68. Atypical antipsychotics and weight gain a systematic review
69. Novel antipsychotics and new onset diabetes
70. Diabetes as a result of atypical antipsychotic drugs: A report of three cases
71. New-onset diabetes mellitus associated with the initiation of quetiapine treatment
72. Clozapine and associated diabetes mellitus
73. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications
74. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment
75. 2A/2C and alpha 2 antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors
76. Ritanserin, imipramine, and placebo in the treatment of dysthymic disorder
77. Response of anxiety and agitation symptoms during nefazodone treatment of major depression
78. Care of the sexually active depressed patient
79. Management of sexual side effects of antidepressant therapy
80. A comparison of drugs versus placebo for the treatment of dysthymia
81. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine
82. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder
83. Antidepressant treatment of the depressed patient with insomnia
84. Treatment issues related to sleep and depression